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Abstract
Aim: A serious syndrome for cancer in-patients, delirium risk increases with age and medical acuity. Screening tools
exist but detection is frequently delayed or missed. We test the ‘Single Question in Delirium’ (SQiD), in comparison
to psychiatrist clinical interview.
Methods: Inpatients in two comprehensive cancer centres were prospectively screened. Clinical staff asked
informants to respond to the SQiD: “Do you feel that [patient’s name] has been more confused lately?”. The primary
endpoint was negative predictive value (NPV) of the SQiD versus psychiatrist diagnosis (Diagnostic and Statistics
Manual criteria). Secondary endpoints included: NPV of the Confusion Assessment Method (CAM), sensitivity,
specificity and Cohen’s Kappa coefficient.
Results: Between May 2012 and July 2015, the SQiD plus CAM was applied to 122 patients; 73 had the SQiD and
psychiatrist interview. Median age was 65 yrs. (interquartile range 54–74), 46% were female; median length of
hospital stay was 12 days (5–18 days). Major cancer types were lung (19%), gastric or other upper GI (15%) and
breast (14%). 70% of participants had stage 4 cancer. Diagnostic values were similar between the SQiD (NPV = 74,
95% CI 67–81; kappa = 0.32) and CAM (NPV = 72, 95% CI 67–77, kappa = 0.32), compared with psychiatrist interview.
Overall the CAM identified only a small number of delirious cases but all were true positives. The specificity of the
SQiD was 87% (74–95) The SQiD had higher sensitivity than CAM (44% [95% CI 41–80] vs 26% [10–48]).
Conclusion: The SQiD, administered by bedside clinical staff, was feasible and its psychometric properties are now
better understood. The SQiD can contribute to delirium detection and clinical care for hospitalised cancer patients.
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Key message
The clinical diagnosis of delirium is often missed, lead-
ing to poor outcomes for cancer inpatients such as in-
creased morbidity, mortality, distress and length of stay.
Improved delirium detection is an important component
of comprehensive cancer care. Compared with a psych-
iatrist interview, the SQiD - a Single Question in Delir-
ium- showed good negative predictive value [NPV 75%
(95%CI 67–81)] and fair agreement [kappa = 0.32
(95%CI 0.08–0.56)]. Specificity of the SQiD was 86% and
sensitivity was 44%. The short Confusion Assessment
Method (CAM) is a very commonly used delirium detec-
tion tool, in our setting the CAM had good specificity
(100%) but a sensitivity of 26% and NPV of 72% (95%CI
67–77). The SQiD can contribute to quality of care for
cancer patients.
Background
Delirium is a syndrome defined in terms of neuro-
cognitive features and level of awareness, with inatten-
tion a salient feature [1]. It is common and associated
with poor outcomes for patients, staff and carers. Delir-
ium disproportionately affects medically unwell people,
is often reversible but diagnosis is frequently missed. To
improve detection, screening for delirium has been ad-
vocated in hospitalised patients [2]. An ideal tool for de-
tecting delirium would have good sensitivity, specificity,
and negative predictive value (NPV) for all sub-types of
delirium [3], be quick to administer and have realistic
training requirements. It would be validated against an
appropriate research standard [3].
Delirium detection tools for hospitalised patients
have been reviewed elsewhere [4, 5], however, with re-
spect to clinical uptake, particularly outside areas where
delirium may be considered core business such as spe-
cialist aged care or perioperative settings, uptake is
largely unknown. Regardless of setting, the use of detec-
tion tools in hospital wards may be constrained by sev-
eral issues such as for example, the need for specific
training, added complexity in administration of compos-
ite measures and the consideration that all tools take at
least a few minutes to administer.
The uptake of routine delirium screening in oncology
in-patient settings is not known; only a few detection
tools have been tested in oncology in-patients; mostly in
“stand-alone” palliative care in-patient units or subsets
of oncology patients such as those referred to palliative
care or psychiatry services. At the time of study design,
three tools, the Mini Mental State Examination (MMSE),
Memorial Delirium Assessment Scale (the MDAS, a de-
lirium severity assessment tool) and the Confusion As-
sessment Method (CAM) [6], were most commonly
reported in delirium detection studies in patients with
cancer. Subsequently, the Nursing Delirium Rating Scale
(Nu-DESC) [7] and “4 A’s test” (4AT) [8] have been
favourably tested in “stand alone” palliative care settings
and Neefjes et al. have compared the Delirium Observa-
tion Screening Scale (DOS) to another delirium rating
tool the Delirium Rating Scale R 98 [9].
All delirium tools have some methodological issues.
The CAM, which has a short version, is the most widely
used delirium detection tool in clinical and research set-
tings. When applied by staff well trained in its adminis-
tration, the CAM achieves overall sensitivity of 94%
(95% confidence interval [CI] 91–97%), and specificity of
89% (95% CI 85–94%) [10]. However, the CAM is less
simple to use and relies heavily on the skill and training
of the operator [6], making it impractical in some clin-
ical settings, especially those with high staff turnover. In
addition, even the short CAM must be accompanied by
a test of cognition such as the mini-cog [10, 11], which
although relatively brief to administer, adds to the total
time and complexity of using it as a screening tool [12].
More recent studies have failed to reproduce in clinical
research settings the excellent psychometric properties
of the CAM when applied in research settings [13, 14].
Feasibility testing for the SQiD, a single-question,
informant-response tool for detecting delirium against
an established reference standard has previously oc-
curred [15]. The Single Question, study setting and ref-
erence standard are unchanged from the feasibility
study.
During the study period, there was a change in the
DSM, from DSM IV R to DSM 5 and throughout the
study the contemporaneous edition of the DSM inter-
view was used, that is either DSM IV R or DSM 5. Of
note, disturbed level of consciousness was removed as
part of the diagnostic criteria for delirium in the change
to DSM 5.
With the overall purpose of decreasing the distress,
morbidity and mortality of delirium by improving delir-
ium detection in hospitalised cancer patients, we de-
signed a novel single question tool for delirium
detection (the SQiD) and compared it to a robust stand-
ard (DSM interview by consultant psychiatrist).
Methods
Study design and setting
This cross-sectional, observational study was undertaken
as part of a higher research degree by the first author
[16]. Patients were recruited from in-patient oncology
wards of two comprehensive cancer centres in Sydney,
Australia. Existing bedside clinicians undertook training
for administration of the CAM. The SQiD was adminis-
tered as part of usual care carried out by ward clinical
staff. There was no specific training for the SQiD; staff
were handed a prompt (see supplementary data) and
instructed that any conversation that followed should be
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as they would normally proceed when questioned by pa-
tients or family [15]. The primary objective was to deter-
mine the negative predictive value (NPV) of the SQiD
versus psychiatrist DSM interview. The secondary objec-
tives were to determine: the NPV of the CAM versus the
interview and comparison of the NPV of the SQiD and
CAM in relation to interview.
Human research and ethics approval, participant
recruitment, consent and study withdrawal
Institutional ethics approval was obtained from the South-
Eastern Sydney Local Health District Human Research
Ethics Committee (approval number LNR 11/156). Written
consent was obtained from each participant or their proxy
if they were unable to give informed consent.
Included patients were adults on a dedicated oncology
ward of participating cancer centres, both were within
university affiliated acute hospitals. Eligible patients were
included regardless of cancer primary site, or stage of dis-
ease. Exclusion criteria are listed in Fig. 1. In order to miti-
gate selection bias, consecutive admissions on nominated
recruitment days were targeted for inclusion. At site two,
recruitment occurred only on a priori nominated days
(Monday to Wednesday) due to staff availability.
Administration of the novel tool (SQiD) and adminis-
tration of the short CAM (hereafter referred to as CAM)
were accepted as consistent with usual care by the eth-
ical review board. Written consent for psychiatrist inter-
view and study participation was specifically sought
from the patient or their proxy prior to approach by the
psychiatrist but consent occurred after SQiD and CAM
administration. This was an intentional part of the study
design in order to mitigate training bias via the educa-
tional nature of the consent or leading nature of psychi-
atric interview should it be administered prior to the
single question [17].
If the patient was unable to give informed consent, a
substitute decision maker was approached. In most in-
stances the SQiD informant was the person (relative,
friend or carer) most practically available who could pro-
vide history. This was designed to mimic psychiatric co-
lateral history but also to be consistent with pragmatic
Fig. 1 Recruitment Flow diagram.Interview Psychiatric Diagnostic and Statistic Manual Interview; SQiD Single Question in Delirium; CAM Short
Confusion Assessment Method
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concerns of the clinical staff. In the study, clinical staff
were asked to use the person most commonly at the
bedside, who they might usually approach with prag-
matic questions about the patient. The patient and infor-
mants were able to withdraw from the study at any time
and were offered the option of consenting for data col-
lected up to withdrawal and where consent for this was
granted, data from these subjects were included for ana-
lyses. All aspects of the final methodology including use
of the SQiD and CAM data from patients who con-
sented to data use but not psychiatrist interview were
accepted by the ethical review board.
Sequence and administration of delirium detection tools
and reference standard used for case ascertainment
Figure 2 shows the order of administration of tools, con-
sent and reference standard. Study flow was designed to
mitigate training or exposure bias of the informant, and
for this reason administration of the SQiD always pre-
ceded the CAM and the psychiatrist interview was per-
formed last. The CAM, SQiD and psychiatrist interview
were all performed by a different assessor, with each
blinded to the results of other tests. The psychiatrists
had access to the patient’s medical record.
Administration of the SQiD
A one-hour, in-service education session on delirium
was delivered by the investigators at each site (MBS and
JL). There was no specific training for the SQiD. Ward
clinicians were given a written prompt (see supplemen-
tary data) with the SQiD phrase and instructed to ad-
minister this verbally and in-person to the most
appropriate relative or friend. The SQiD question was
not administered as a written questionnaire.
The SQiD was framed: “Do you feel that [patient’s name]
has been more confused lately?” An interview guide or
prompt was used to record the SQiD informant’s yes or no
answer to the Single Question together with some demo-
graphic information. The text is intended as a prompt for
staff administering the SQiD and was not intended to be
handed to the SQiD informant. Although only a dichotom-
ous response of “yes” or “no” was recorded by the person
administering the SQiD, discussion leading to the decision
of which answer was appropriate was not discouraged. This
was intended to reflect the real clinical interaction between
staff and family/carers a question may encourage. Patients
were not specifically included or excluded from this discus-
sion. The SQiD was preferentially administered in person
by bedside clinical staff but, if necessary, could be adminis-
tered over the phone, and was at times administered by a
(supervised) health care student as they form part of the
usual clinical care team.
Confusion assessment method (CAM) training and
administration
The Short CAM [18] was the CAM version utilised
throughout this study. The CAM was administered by
senior palliative care and oncology nurses (with 3–10
years of experience on the palliative care consultation
team) who received training from a senior aged care
Fig. 2 Order of administration of tests, consent and diagnostic
reference standard. Interview Psychiatric Diagnosic and Statistic
Manual Diagnostic Interview; SQiD Single Question in Delirium; CAM
Short Confusion Assessment Method; ; IQR Interquartile range
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nurse familiar with the CAM in daily clinical practice in
the aged care assessment team. Study staff administering
the CAM were also provided with the Short CAM train-
ing manual instructions and tasked with following them
[18]. As we wished to balance the rigorous specifications
of CAM user training with the real world constrains of
clinical staff on the oncology ward, formal inter-rater re-
liability was not tested. The Mini-Cog [11] was used as
the short cognitive test pre-requisite to CAM
administration.
Participant interview by consultant liaison psychiatrist
A post-fellowship consultant liaison psychiatrist (special-
ist in psychosomatic medicine) assessed each patient in
a brief interview, according to the the contemporaneous
Diagnostic and Statistical Manual of Mental Disorders
(DSM) [19, 20]; classification included delirium motoric
subtype. Our aim was for the psychiatric interview to be
performed within approximately 24 h of the SQiD and
CAM. The psychiatrist had access to the clinical record
and could assess fluctuation of symptoms as required for
the DSM diagnoses and was also tasked with recording
motoric subtype of delirium [21].
Statistical analysis
Descriptive information is presented in tabular format.
Categorical data are presented as total numbers and pro-
portions, and continuous data as medians and interquar-
tile ranges. The difference between groups was tested
using Chi-squares and Mann-Whitney tests. Criterion
validity between SQiD and CAM tests was measured by
estimating diagnostic values of sensitivities, specificities,
positive predictive and negative predictive values using
the DSM diagnosis as the diagnostic reference standard.
Sensitivity was defined as proportion of patients with de-
lirium who were correctly identified using a test [22].
Specificity was defined as the proportion of patients
without delirium who were correctly identified using a
test [22]. Cohen’s kappa statistic (kappa) was used to de-
termine the proportion agreement corrected for chance
[23]. Kappa values above 0.75 denote excellent agree-
ment, 0.40 to 0.75 fair to good agreement, 0.21 to 0.4 as
fair and below 0.20 poor agreement. Data management
and analysis were undertaken using SAS software, ver-
sion 9.3 (SAS Institute, Cary NC).
A maximum sample size of 133 was calculated to de-
tect 50% sensitivity (“worst case” scenario) with 20% pre-
cision, with an alpha of 5% and an assumed delirium
prevalence of 18% [24]. A sample size of 194 was needed
to achieve 90% sensitivity with 5% precision.
In instances where there was missing data, participants
were only included if they had two complete assessments
where data could be used for the respective comparisons.
Data for patients who completed the usual care
components (SQiD and CAM) but did not progress to
consent for data to be included in the study or did not
consent or withdrew consent were not included in the
analysis.




analysis N = 122
Gender
Male 33 (42%) 62 (51%)
Female 39 (53%) 56 (46%)
Admitting team
Medical Oncology 47 (64%) 85 (70%)
Radiation Oncology 17 (23%) 22 (18%)
Palliative Care 7 (10%) 9 (7%)
Admission indication
Symptom management 55 (75%) 88 (72%)
Tumour type
Lung 14 (19%) 23 (20%)
Gastric and other upper GI 11 (15%) 15 (12%)
Breast 10 (14%) 14 (11.5%)
Prostate 3 (4%) 13 (11%)
Colon 8 (11%) 9 (7%)
Other 23 (31.5%) 39 (32%)
Tumour stage
Stage I or II 8 (11%) 10 (8%)
Stage III 12 (16%) 19 (15%)
Stage IV 50 (68.5%) 85 (69.7%)
Site of metastasis
No documented metastasis 20 (27%) 32 (26%)
Bone 18 (25%) 24 (20%)
Liver 10 (14%) 13 (11%)
Lung 4 (5.5%) 7 (6%)
Brain 3 (4%) 9 (7%)
Multiple sites 12 (16%) 25 (20.5%)
Unknown/missing 6 (8%) 10 (8%)
ECOG Score
1 or less 22 (30%) 31 (25%)
2 22 (30%) 40 (33%)
3 or more 19 (26%) 34 (28%)
Unknown/missing 10 (14%) 17 (14%)
SQiD informant cohabitation
with patient
41 (56%) 69 (57%)
Median (IQR) Median (IQR)
Age 68 (60.5–78) 68 (56–77.5)
Australia-Modified Karnofsky Score 70 (50–80) 70 (50–70)
GI Gastro intestinal, IQR Interquartile range
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Results
Recruitment occurred between 7th April 2012 – 8th
May 2015 at site one, and from the 19th of March 2014
– 2nd of September 2015 at site two. A total of 1175 pa-
tients were identified, 509 of whom were assessed for eli-
gibility, with a total of 142 patients consented to be part
of the study (Fig. 1).
The median age across all consenting participants was
68 years (IQR 56–77.5 n = 122) and of these, 56 (47%)
were female (Table 1). Major cancer types were lung 14
(19%), gastric or other upper GI 11 (15%) and breast 10
(14%). A third of the patients had stage IV cancer, and
cerebral metastases were present in 9 (7%) cases. In
total, 88 (72%) of 122 participants admissions were for
symptom management. The SQiD respondent and the
patient resided together for 69 (57%) participants. Me-
dian length of hospital stay was 12 days (IQR 5–18). Me-
dian Australia-modified Karnofsky Performance Status
(AKPS) [25] was 70 (IQR 50–70). The median AKPS
score for the first centre was 70 (IQR 50–80), and for
the second centre was 65 (IQR 60–70) with no signifi-
cant difference in the distributions between the two cen-
tres (Wilcoxon Two-sample test z = − 0.02, p = 0.983.
Compared with the source population, study partici-
pants were significantly older (median age 68 vs 65, p-
value 0.006), and had longer length of stay (median 12
vs 5 days, p-value< 0.001). (Table 2) There were no dif-
ferences in gender distribution between participants and
non-participant groups. The median time difference be-
tween administration of the SQiD and the psychiatrist
interview was 26 h (IQR 19–71), and 24 h (IQR 1–23)
between the CAM and psychiatrist interview.
The diagnosis of delirium based on psychiatrist inter-
view was made in 27/71 (38%). Motoric subtype of those
interviewed was 4/71 hyperactive, 16/71 hypoactive, and
6/71 mixed [21]. The SQiD identified 18 cases of delir-
ium, a third of which were true positives. The primary
endpoint of NPV of the SQiD compared to psychiatrist
interview was 73% (95% CI 65–79) (Table 3).
Among those patients who completed all tests (n = 67),
both SQiD and CAM had similar NPV (75% v 72%) and
kappa coefficient (0.32), with SQiD exhibiting higher
sensitivity (44% vs 26%) but lower specificity (87% vs
100%). Of the 16 patients with hypoactive delirium diag-
nosed by psychiatrist interview, the SQiD identified five
of the cases, while the CAM identified one. Overall, the
CAM identified a low number of delirious patients, but
all CAM positive patients identified delirium correctly.
The remaining primary and secondary endpoints are
presented in Table 3.
Discussion
Our study demonstrates that the SQiD has good per-
formance and is comparable with the CAM in terms of
NPV against psychiatric interview, the diagnostic refer-
ence standard. This is an important attribute of the
study as without a robust standard applied systematically
across a validation study, in keeping with recommended
delirium diagnosis methodology [3], the validity of a de-
tection tool cannot be established. Our study found fair
correlation of both SQiD and CAM in relation to the
reference standard. The CAM had a better PPV but a
low sensitivity, whereas the SQiD had better sensitivity.
The CAM however, found much lower number of pa-
tients with delirium than the reference standard, but
with the caveat that all those identified as being delirious
or non-delirious by the CAM were correctly identified,
hence the contrast between Sensitivity (26%) and Specifi-
city (100%) of the CAM.
Methodological strengths of our study include a clear
description of patient characteristics and setting that
mitigated case ascertainment bias and the method which
prevented training bias due to study flow.
The use of an accurate and reproducible reference stand-
ard with a clear description of reference-rater training and
characteristics is of central importance. This was a prag-
matic, clinically embedded, ‘real world’ study. The SQiD is
simple and provides a pragmatic approach to support up-
take and also enabled families to be involved in discussions
with bedside clinicians regarding delirium. Informal feed-
back suggests it has good face validity to engage staff in ac-
tively seeking delirium. A better understanding of what
happens after the SQiD question is asked may benefit fu-
ture iterations and aid an understanding of the role for the
SQiD in staff education and the promotion of helpful dis-
cussion between carers and staff.
Current guidelines do not support routine delirium
screening in Oncology settings due to lack of evidence
[26], they do however provide the following advice “any
changes in cognitive or emotional behaviour or
Table 2 Comparison of characteristics of participants versus background population
Background population N = 2352 Primary analysis n = 73 Secondary analysis n = 122
Female (%) 45% 54%ns p-value = 0.146 47% ns p-value = 0.676
Age Median (IQR) 65 (54–74) 68 (60.5–78)* p-value = 0.010 68 (56–77.5)* p-value = 0.006
LOS Median (IQR) 5 (3–10) 12.5 (6–18.5)* p-value < 0.001 12 (5–18)* p-value < 0.001
ns – non-significant difference between participants and background population
*Statistically significant differences between participants and background population, tested using Mann-Whitney test
IQR Interquartile Range, LOS Length of stay
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psychomotor activity suggestive of delirium are present,
a trained healthcare professional with expertise in evalu-
ating delirium should carry out a clinical assessment to
confirm the diagnosis of delirium” which lends support
to engaging staff and family in detecting this change.
While the SQiD does not replace clinical assessment its
NPV may support clinicians in identifying patients for
further review.
Of the 16 patients with hypoactive delirium, 6 were
identified on SQiD, the CAM identified only one. The
detection of hypoactive delirium is an important consid-
eration in delirium detection tools as typically hypoac-
tive delirium poses more difficulties for clinical
identification. Given the small numbers in each motoric
sub-group, this observation needs to be interpreted with
caution, however this is one aspect of the SQiD which
may support further investigation.
As the SQiD is not directly asked of the patient, it is
not important that patients speak English. This may
even be an advantage but at this point it is a theoretical
advantage not tested by this study which was con-
strained by exclusion of patients with insufficient English
fluency for consent and psychiatrist interview.
Limitations of our study relate to a non-consecutive
sample and exclusion of some patient groups. The study
population had some statistically-significant differences
to the source population – they were older and had lon-
ger length of stay. Further it is of note that delirium de-
tection rates in our sample are not presented as
representative of the base population and cannot there-
fore be used to estimate delirium incidence or preva-
lence. The rates detected in the study population were
however not dissimilar to incidence or prevalence estab-
lished in several other medical in-patient cohorts [13,
14, 24, 27–29]. A further limitation was that SQiD ad-
ministration appeared to be dependent on prompting by
senior staff, making recruitment subject to variation due
to competing demands and staffing. The time between
SQiD, CAM and psychiatric interview was also generally
longer than anticipated in the protocol. This can have
implications for diagnosis as delirium symptoms fluctu-
ate over time. There is a possibility of recruitment centre
bias however in terms of Australia-modified Perform-
ance Status (AKPS) [25] no bias was detected. Lastly, the
study did not reach the planned sample size, which re-
sulted in lower power and wider confidence intervals.
Although CAM training for study staff was conducted
it fell short of that recommended for diagnostic pur-
poses and we did not achieve the sensitivity and specifi-
city in using the CAM that has been reported elsewhere
[9]. One of the reasons the CAM was included as a com-
parator to the SQiD was to determine if it was an option
for routine use in our clinical setting. With the training
possible in the cancer clinical context this was not the
case, and we note that other recent studies have re-
ported similar short-comings in training staff so that
optimum sensitivity and specificity of the CAM has not
been achieved in those clinical and clinical research
settings [12, 13].
A further limitation is that the only information gath-
ered about the SQiD informant was co-habitation with
the patient. Cognitive testing to understand how family
and carers interpret the SQiD question, the subsequent
discussion, and understanding of the meaning of ques-
tion prior to the study may be of relevance, and is rec-
ommended for consideration in future studies.
Finally, a number of patients in our study were ex-
cluded due to lack of English fluency (n = 43). There-
fore, conclusions about the utility of the SQiD in
patients across cultural and linguistic backgrounds
other than that of English speakers remains untested.
Similarly, the SQiD may be of lower utility for pa-
tients who live alone or have limited contact with
other people. Nevertheless, of 142 patients in our
Table 3 Comparison of delirium test diagnostic values and measures of agreement
PPV Positive predictive value, NPV Negative predictive value, SQiD Single Question in Delirium, CAM Short Confusion Assessment Method, P/DSM Psychiatrist
DSM interview.
Cohen’s kappa statistic (kappa) values above 0.75 denote excellent agreement, 0.40 to 0.75 fair to good agreement, 0.21 to 0.4 as fair and below 0.20 poor
agreement.* Restricted to patients who had all three measures recorded, SQiD, CAM and P/DSM N = 67.
Primary analysis.
Secondary analysis
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study, only five were excluded due to not having a
person available to answer the SQiD.
Implications for training and practice
The SQiD may engage nurses, medical staff, carers and/
or patients in discussion regarding the components of
syndromic delirium. The use of the SQiD by clinical staff
may reinforce the concept that delirium is an important
medical issue for staff, patients and family/carers.
Implications for research
Other studies have compared short tests of cognition or
attention [4, 8, 12, 30, 31] however, to our knowledge,
having a clinician directly approach the main carer with a
conversational approach and a simple question regarding
recent changes in cognition, although it makes common
sense/good clinical practice, has not been previously eval-
uated. Future research questions may focus on the content
of the discussion that ensues following administration of
the SQiD, and the ability of the tool to engage staff and
family/carers in looking for changes that would indicate a
need for further clinical delirium assessment.
The combination of a detection tool with high sensi-
tivity followed by one with high specificity may be a use-
ful approach to screening and could be addressed in
future studies. Since inception of this study other short
and brief tools have appeared in the peer review litera-
ture, including the 4AT [30] and more recently the delir-
ium RADAR [31]. These tools are promising either
alone or in combination, however they may not have the
same qualities of engaging carers and staff that is pos-
sible with the SQiD, which again raises hypotheses relat-
ing to combined administration of short tests.
Conclusion
The SQiD had NPV comparable to the CAM when used
with a pragmatic level of training in our clinical setting.
The SQiD has favourable psychometric properties; on
face value it is feasible and pragmatic for staff, accept-
able to carers and patients and engages staff, family and
carers in a shared and educational goal. The SQiD can
contribute to delirium detection and clinical care for
hospitalised cancer patients.
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